Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02529891

Acronym

LAVOLEX

Enrollment

Registered

2015-08-20

Start date

2014-08-08

Completion date

2017-10-17

Last updated

2017-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Chronic Obstructive Pulmonary Disease, COPD, Volatile Organic Compounds, Exacerbation

Brief summary

Exacerbations of the disease are a hallmark of Chronic Obstructive Pulmonary Disease (COPD), affecting the decline of pulmonary function, quality of life and increasing morbidity. The use of validated biomarkers could help to identify the etiology of exacerbation and to prescribe antibiotherapy when indicated. The analysis of exhaled air allows measuring different volatile organic compounds (VOC) which reflect local or systemic inflammation and oxidative stress. The relationship between the presence of some of these compounds and the exacerbation of COPD has never been studied. The aim of this study is to identify a cluster of VOC in COPD patients during an acute exacerbation of the disease, compared to a stable condition (3 months after discharge). Investigators also will seek for a relationship between VOC and the etiology of exacerbation (bacterial, viral, inflammatory).

Interventions

OTHERMeasurement of VOC in exhaled air

Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

of COPD group: * COPD stages 2 and 3 of GOLD score (30 ≤ forced expiratory volume at one second (FEV1) \< 80% of predicted value), * exacerbation confirmed clinically (increased dyspnea, cough or expectorations \> 48 hours) Inclusion Criteria of non COPD group: * No smoker (\<100 cigarettes/year)

Exclusion criteria

of COPD group: * Diagnosis of COPD not confirmed. * Instable clinical status with respiratory failure and indication of mechanical ventilation. * Bronchodilator treatment changed * Antibiotic treatment started in the 10 last days before admission

Design outcomes

Primary

Measure	Time frame	Description
Spectrum of VOC measured with a portable mass spectrometer system	Day 1 (within 48 hours after hospital admission for exacerbation of COPD)	Spectrum of VOC in exhaled air in patients with COPD compared to those of control subjects. It is measured with a portable mass spectrometer system.

Secondary

Measure	Time frame	Description
Variation in VOC spectrum in COPD patients measured with a portable mass spectrometer system	3 months after hospital discharge	Variation in VOC spectrum in COPD patients during exacerbation and in stable condition (3 months later). It is measured with a portable mass spectrometer system.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026